Section Arrow
Quote
NEUP.NASDAQ
- Neuphoria Therapeutics Inc
(Financial Status)
Quotes are at least 15-min delayed:2025/11/20 08:48 EST
Pre Market
Last
 4.41
-0.01 (-0.23%)
Bid
4.41
Ask
4.82
High 4.44 
Low 4.41 
Volume 1330 
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
4.42 
1-M High
-- 
Volume 
-- 
Bid
4.41
Ask
4.82
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
10.42M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.23/-5.17
Enterprise Value
10.42M
Balance Sheet
Book Value Per Share
8.06
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
Pre Market 22.8 +0.2 +0.88%
ZVRAZevra Therapeutics----0.000%-- 
Pre Market 9.7625 +0.0825 +0.85%
ZURAZura Bio Limited----0.000%-- 
Pre Market 4 +0.13 +3.36%
ZNTLZentalis Pharmaceuticals----0.000%-- 
Pre Market 1.3568 +0.0268 +2.02%
ZLABZai Lab Limited----0.000%-- 
Pre Market 20.93 +0.43 +2.10%
Quotes are at least 15-min delayed：2025/11/20 08:48 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorderswith high unmet medical need.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.